NanoViricides

Historical price data

NanoViricides is pioneering a 'post-immunotherapeutic' platform to combat viral diseases with its unique nanoviricide technology, which mimics host cell receptors to trap and dismantle viruses. The company has advanced its lead broad-spectrum candidate, NV-387, into a Phase 2 trial for MPox in the Democratic Republic of Congo and maintains a deep pipeline targeting herpesviruses, HIV, influenza, and neglected tropical diseases. With its own cGMP-capable manufacturing facility in Shelton, CT, NanoViricides aims to control both extracellular virus spread and intracellular replication, addressing a multi-billion dollar market for antiviral therapeutics.

Biomimetic nanomedicine platform creating polymeric micelles ('nanoviricides') that mimic host cell receptors to bind to, engulf, and destroy enveloped virus particles extracellularly, with potential for targeted intracellular drug delivery.

NanoViricides faces competition from large pharma and biotech companies developing vaccines, monoclonal antibodies, and small molecules for viral diseases. Its main differentiation is its novel 'bind-engulf-destroy' mechanism designed to be broad-spectrum and mutation-resistant, acting independently of the immune system—a potential advantage over antibodies and a different approach than intracellular small molecule inhibitors.